Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167767 | 0.90 | HTR6 (0.45) | NAMPTHTR6CYP2C9KMT2ACYP2D6 | |
| SCHEMBL26703744 | 0.85 | HTR6 (0.62) | HTR6KMT2AKDM4CPLAUP2RX7 | |
| SCHEMBL30167726 | 0.82 | NAMPT (0.45) | NAMPTHTR6KMT2A | |
| SCHEMBL30167661 | 0.81 | NAMPT (0.49) | NAMPT | |
| SCHEMBL173961 | 0.81 | NAMPT (0.49) | NAMPT | |
| SCHEMBL30167680 | 0.79 | HTR6 (0.45) | NAMPTHTR6KDM4C | |
| SCHEMBL30167565 | 0.78 | NAMPT (0.45) | NAMPTHTR6CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL30167676 | 0.76 | NAMPT (0.48) | NAMPTHTR6KMT2AKDM4C | |
| SCHEMBL30167764 | 0.76 | CYP11B1 (0.50) | KDM4C | |
| SCHEMBL30167862 | 0.75 | CYP2C19 (0.53) | NAMPTHTR6KMT2ACYP2C19P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NAMPT 1/4885HTR6 1677/4885CYP2C9 772/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885HTR6 1683/4885CYP2C9 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.